GlycoTherapeutics wants to modify the sugar layer of cancer cells to slow down the growth of cancer cells metastases of malignant tumors in the body. This allows the immune system to detect and fight cancer cells more effectively. The innovative approach is currently in the preclinical phase, but is a promising new approach in the fight against cancer.
Studies
GlycoTherapeutics was founded in 2022 by Johan Pijnenborg, who received his PhD from Radboud University. The research behind the spin-off is the result of years of efforts by Radboud University's glycobiology research groups, led by chemists Thomas Boltje and Christian Büll. In his PhD Pijnenborg worked on the development of new chemical tools for the study and perturbation of carbohydrate processing enzymes. The team has acquired patents for innovative molecules that form the basis for the new therapy. Although much work remains to be done before clinical trials can begin, Pijnenborg hopes to reach the clinical phase in the near future.
Glycobiology
The founding of GlycoTherapeutics could indicate new opportunities of glycobiology in oncology and the innovative therapy could potentially be applicable for different types of cancer.